CRSP
CRISPR Therapeutics AG
There isn't enough reported data to score CRSP yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CRSP Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CRSP's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CRSP PE Valuation
CRSP has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CRSP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CRSP's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CRSP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.69 | +$0.87 |
| Q2 2026 | -$4.71 | +$0.69 |
| Q1 2026 | -$6.17 | -$1.68 |
| Q4 2025 | -$6.47 | -$2.13 |
| Q3 2025 | -$5.56 | -$2.75 |
| Q2 2025 | -$5.40 | -$2.19 |
| Q1 2025 | -$4.49 | -$1.79 |
| Q4 2024 | -$4.34 | -$2.40 |
CRSP is still losing money, but less than at its worst: $4.69 per share over the past year, against $8.52 at its worst in late 2022.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CRSP on earnings quality, reporting a profit while its opponent remains loss making.
CRSP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.7M | +1325% |
| Q2 2026 | $10.2M | +1041% |
| Q1 2026 | $1.5M | +69% |
| Q4 2025 | $864K | -98% |
| Q3 2025 | $889K | +48% |
| Q2 2025 | $892K | +73% |
| Q1 2025 | $865K | +72% |
| Q4 2024 | $35.7M | -82% |
CRSP's revenue is recovering but still below its 2021 peak: $13M last quarter, up 1325% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1026% | +13828 points |
| Q2 2026 | -1152% | +24557 points |
| Q1 2026 | -8933% | +8226 points |
| Q4 2025 | -17913% | -17732 points |
| Q3 2025 | -14855% | +3439 points |
| Q2 2025 | -25709% | +3548 points |
| Q1 2025 | -17159% | +10735 points |
| Q4 2024 | -181% | -216 points |
CRSP's operating margin was −1026% last quarter, up 13828 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CRSP on profitability, with a higher operating margin.
CRSP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.1M | -$5.4M |
| Q2 2026 | -$84.1M | +$29.9M |
| Q1 2026 | -$109.4M | -$55.2M |
| Q4 2025 | -$93.1M | -$42.8M |
| Q3 2025 | -$84.7M | +$22.4M |
| Q2 2025 | -$114M | -$17.7M |
| Q1 2025 | -$54.2M | -150% |
| Q4 2024 | -$50.3M | +$46.5M |
CRSP has burned cash in almost every quarter: −$377M over the past year, against −$303M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CRSP on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRSP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +227K shares |
| 1 year | +6% | +5.4M shares |
| 3 years | +22% | +17.3M shares |
| 5 years | +27% | +20.5M shares |
| Available history | +61% | +36.5M shares |
CRSP has 97M diluted shares, up 6% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CRSP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CRSP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -2.1x | Net Cash |
| Q4 2021 | -2.4x | Net Cash |
| Q3 2021 | -2.4x | Net Cash |
| Q2 2021 | -3.6x | Net Cash |
| Q2 2020 | -329.4x | Net Cash |
| Q1 2020 | -32.3x | Net Cash |
| Q4 2019 | -18.3x | Net Cash |
CRSP has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CRSP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 17.4 | Oversold |
CRSP's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CRSP PE vs Healthcare Sector
| Metric | CRSP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CRSP has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CRSP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $50.7 | 16% below |
| 20 week MA | $52.5 | 19% below |
| 50 week MA | $52.7 | 19% below |
| 100 week MA | $50.8 | 16% below |
| 200 week MA | $53.0 | 20% below |
CRSP is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CRSP on trend strength, trading above more of its moving averages.
CRSP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $168.5 | +155% |
| 2021 | $168.5 | $82.2 | -51% |
| 2022 | $82.2 | $44.1 | -46% |
| 2023 | $44.1 | $62.6 | +42% |
| 2024 | $62.6 | $40.0 | -36% |
| 2025 | $40.0 | $55.1 | +38% |
| 2026 YTD | $55.1 | $42.6 | -23% |
CRSP's yearly returns have swung widely, from +155% in 2020 to −51% in 2021. It's down 23% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CRSP on returns for 2026, with the stronger performance.